Inventor · disambiguated record
Aaron R. Kunzer
Also filed as: KUNZER AARON · KUNZER AARON R
44 granted patents·46 pending applications·1,516 citations·filing 2001–2024
98Inventor score
Top patents by PatentIndex Score
90 records- 0198US8546399B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesBRUNCKO MILAN·Filed 2010·Granted Oct 1, 2013·100 cites·24 claims
- 0298US7973161B2Apoptosis promotersABBOTT LAB·Filed 2006·Granted Jul 5, 2011·70 cites·5 claims
- 0398US7767684B2Apoptosis promotersABBOTT LAB·Filed 2005·Granted Aug 3, 2010·107 cites·7 claims
- 0498US7642260B2Apoptosis promotersABBOTT LAB·Filed 2005·Granted Jan 5, 2010·82 cites·2 claims
- 0598US7390799B2Apoptosis promotersABBOTT LAB·Filed 2006·Granted Jun 24, 2008·331 cites·12 claims
- 0698US6720338B2N-acylsulfonamide apoptosis promotersABBOTT LAB·Filed 2001·Granted Apr 13, 2004·98 cites·9 claims
- 0797US9174982B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Nov 3, 2015·38 cites·7 claims
- 0897US8686136B2Apoptosis promotersABBVIE INC·Filed 2012·Granted Apr 1, 2014·20 cites·2 claims
- 0997US8586754B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2010·Granted Nov 19, 2013·59 cites·8 claims
- 1097US8563735B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2009·Granted Oct 22, 2013·72 cites·4 claims
- 1197US8354404B2Apoptosis promotersABBOTT LAB·Filed 2011·Granted Jan 15, 2013·39 cites·8 claims
- 1297US8173811B2Apoptosis promotersBRUNCKO MILAN·Filed 2010·Granted May 8, 2012·50 cites·4 claims
- 1397US7754886B2N-acylsulfonamide apoptosis promotersABBOTT LAB·Filed 2009·Granted Jul 13, 2010·34 cites·18 claims
- 1497US7709467B2Apoptosis promotersABBOTT LAB·Filed 2008·Granted May 4, 2010·50 cites·10 claims
- 1597US7504512B2N-acylsulfonamide apoptosis promotersABBOTT LAB·Filed 2004·Granted Mar 17, 2009·58 cites·18 claims
- 1696US8614318B2Apoptosis promotersBRUNCKO MILAN·Filed 2006·Granted Dec 24, 2013·37 cites·2 claims
- 1796US8084607B2Apoptosis promotersBRUNCKO MILAN·Filed 2009·Granted Dec 27, 2011·43 cites·5 claims
- 1895US8343967B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBOTT LAB·Filed 2012·Granted Jan 1, 2013·32 cites·2 claims
- 1994US9315488B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2015·Granted Apr 19, 2016·13 cites·2 claims
- 2094US8952157B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Feb 10, 2015·22 cites·5 claims
- 2194US8426422B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesHEXAMER LAURA A·Filed 2010·Granted Apr 23, 2013·49 cites·4 claims
- 2293US7906505B2Apoptosis promotersABBOTT LAB·Filed 2010·Granted Mar 15, 2011·18 cites·4 claims
- 2392US8940737B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Jan 27, 2015·7 cites·10 claims
- 2491US9303025B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Apr 5, 2016·11 cites·4 claims
- 2591US8338466B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesKUNZER AARON R·Filed 2010·Granted Dec 25, 2012·15 cites·6 claims
- 2690US9072748B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·10 claims
- 2789US10676485B2Macrocyclic MCL-1 inhibitors and methods of useABBVIE INC·Filed 2018·Granted Jun 9, 2020·2 cites·2 claims
- 2889US9125913B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Sep 8, 2015·10 cites·6 claims
- 2989US7910742B2Survivin inhibitorsABBOTT LAB·Filed 2006·Granted Mar 22, 2011·9 cites·1 claims
- 3088US8889675B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Nov 18, 2014·3 cites·9 claims
- 3187US7981888B21-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivativesABBOTT LAB·Filed 2008·Granted Jul 19, 2011·8 cites·7 claims
- 3287US2024285611A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 3386US9266877B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Feb 23, 2016·2 cites·2 claims
- 3486US9227963B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Jan 5, 2016·2 cites·2 claims
- 3586US2025313572A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 3686US2025019364A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2024·Application pending·0 cites
- 3784US8188077B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesDING HONG·Filed 2011·Granted May 29, 2012·8 cites·5 claims
- 3884US2025177374A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2024·Application pending·0 cites
- 3983US2024043404A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 4082US11897864B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2022·Granted Feb 13, 2024·0 cites·27 claims
- 4182US2024228509A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2023·Application pending·0 cites
- 4281US2025092062A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 4378US2023399340A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 4477US9877958B2Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2016·Granted Jan 30, 2018·1 cites·16 claims
- 4577US9844547B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2015·Granted Dec 19, 2017·1 cites·10 claims
- 4677US2024058450A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2022·Application pending·0 cites
- 4777US2022259226A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 4876US9035047B27-substituted indole Mcl-1 inhibitorsABBVIE INC·Filed 2013·Granted May 19, 2015·1 cites·4 claims
- 4975US2023183261A1Macrocyclic MCL-1 Inhibitors and Methods of UseABBVIE INC·Filed 2022·Application pending·0 cites
- 5075US2022315555A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 90 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Aaron R. Kunzer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →